BTMD: 分析师目标 $4 — AI 分析 (4月 2026)

biote Corp. operates a medical practice-building business focused on hormone optimization. The company provides a platform for practitioners to optimize patient hormone levels and offers bioidentical hormone therapies and dietary supplements.

Key Facts: Price: $1.59 Analyst Target: $3.75 AI Score: 47/100 Sector: Healthcare

公司概况

概要：

biote Corp. revolutionizes hormone optimization with its practitioner platform and bioidentical hormone therapies, driving growth through personalized patient care and a high-margin supplement business, positioning it as a leader in the expanding wellness market and reflected in its P/E of 2.43.

BTMD是做什么的？

biote Corp., founded in 2011 and headquartered in Irving, Texas, operates within the rapidly growing hormone optimization space. The company provides a comprehensive platform for Biote-certified practitioners, enabling them to address hormone imbalances in patients through bioidentical hormone therapies and personalized treatment plans. Biote's approach involves optimizing hormone, vitamin, and mineral levels, supported by the prescription of bioidentical hormones and the recommendation of Biote-branded dietary supplements. These supplements are designed to complement hormone therapies and enhance patient outcomes. In addition to its practitioner platform and supplements, Biote sells sterile pellet insertion kits for both men and women, facilitating the delivery of bioidentical hormone therapies. The company's business model focuses on empowering practitioners with the tools and resources needed to deliver effective hormone optimization treatments, while also generating revenue through product sales and platform usage. Biote's commitment to innovation and patient care has established it as a key player in the evolving wellness market.

BTMD的投资论点是什么？

biote Corp. presents a notable market position due to its strong position in the expanding hormone optimization market. The company's high gross margin of 72.2% and a P/E ratio of 2.43 indicate profitability and potential for growth. Key value drivers include the increasing demand for personalized wellness solutions and the growing network of Biote-certified practitioners. Upcoming catalysts include expansion of the Biote-branded product line and strategic partnerships with healthcare providers. BTMD may be worth researching for its growth potential and established market presence.

BTMD在哪个行业运营？

biote Corp. operates in the medical care facilities industry, within the broader healthcare sector. The hormone optimization market is experiencing significant growth, driven by increasing awareness of hormone imbalances and the demand for personalized wellness solutions. The competitive landscape includes companies offering hormone therapies, dietary supplements, and practice management solutions. Biote differentiates itself through its comprehensive platform for practitioners and its focus on bioidentical hormone therapies. Competitors include ABOS, ACTU, ANIK, INO, and JYNT.

Medical - Care Facilities

Healthcare

BTMD有哪些增长机遇？

Expansion of Biote-Certified Practitioner Network: Biote can significantly expand its revenue by increasing the number of Biote-certified practitioners. The market for hormone optimization is growing, and more practitioners are seeking comprehensive solutions. By offering attractive incentives and training programs, Biote can attract new practitioners to its platform. This expansion will drive increased sales of Biote-branded products and pellet insertion kits, fostering revenue growth.
Development and Launch of New Biote-Branded Products: Biote has the opportunity to develop and launch new dietary supplements and hormone therapies to address specific patient needs. By investing in research and development, Biote can create innovative products that differentiate it from competitors. The market for dietary supplements is substantial, and new product launches can drive significant revenue growth. The timeline for new product development is approximately 12-18 months.
Strategic Partnerships with Healthcare Providers: Biote can establish strategic partnerships with hospitals, clinics, and wellness centers to expand its reach and market presence. These partnerships can provide access to new patient populations and referral networks. By collaborating with established healthcare providers, Biote can increase awareness of its platform and products. The timeline for establishing strategic partnerships is approximately 6-12 months.
International Expansion into New Markets: Biote can expand its operations into international markets to capitalize on the growing demand for hormone optimization worldwide. By adapting its platform and products to meet the needs of different regions, Biote can tap into new revenue streams. The market for hormone therapies is growing globally, and international expansion can drive significant revenue growth. The timeline for international expansion is approximately 18-24 months.
Increased Focus on Patient Education and Awareness: Biote can invest in patient education and awareness campaigns to drive demand for hormone optimization therapies. By providing valuable information and resources to patients, Biote can empower them to take control of their health. Increased patient awareness will lead to more consultations with Biote-certified practitioners and increased sales of Biote-branded products. The timeline for implementing patient education campaigns is ongoing.

Market Cap of $0.11B reflects the company's current valuation in the hormone optimization market.
P/E ratio of 2.43 suggests the company is undervalued compared to its earnings.
Profit Margin of 14.7% demonstrates the company's ability to generate profit from its revenue.
Gross Margin of 72.2% indicates strong pricing power and efficient cost management.
Beta of 1.15 suggests the stock is slightly more volatile than the market.

BTMD提供哪些产品和服务？

Provides a platform for Biote-certified practitioners.
Offers bioidentical hormone therapies.
Sells Biote-branded dietary supplements.
Provides sterile pellet insertion kits for hormone therapy.
Optimizes patient hormone, vitamin, and mineral levels.
Offers training and certification programs for practitioners.
Supports practitioners in building their medical practices.

BTMD如何赚钱？

Generates revenue through the sale of Biote-branded dietary supplements.
Earns revenue from the sale of sterile pellet insertion kits.
Collects fees from practitioners for access to the Biote platform and training programs.

Biote-certified practitioners who use the platform to treat patients.
Patients seeking hormone optimization therapies.
Hospitals, clinics, and wellness centers that partner with Biote.

Established network of Biote-certified practitioners provides a barrier to entry.
Proprietary platform and training programs create a competitive advantage.
Strong brand reputation and patient loyalty.
High gross margins indicate pricing power and efficient cost management.

什么因素可能推动BTMD股价上涨？

Upcoming: Expansion of Biote-branded product line to include new dietary supplements and hormone therapies.
Upcoming: Strategic partnerships with hospitals and clinics to expand market reach.
Ongoing: Increasing demand for personalized wellness solutions.
Ongoing: Growing network of Biote-certified practitioners.
Ongoing: Positive clinical data supporting the efficacy of Biote therapies.

BTMD的主要风险是什么？

Potential: Changes in regulations governing hormone therapies.
Potential: Increased competition from alternative therapies.
Ongoing: Reliance on Biote-certified practitioners for revenue generation.
Ongoing: Economic downturn impacting patient spending.
Potential: Negative publicity regarding hormone optimization.

BTMD的核心优势是什么？

Established platform for hormone optimization.
Strong brand reputation and patient loyalty.
High gross margins.
Growing network of Biote-certified practitioners.

BTMD的劣势是什么？

Reliance on Biote-certified practitioners for revenue generation.
Limited geographic reach.
Competition from established healthcare providers.
Potential regulatory risks associated with hormone therapies.

BTMD有哪些机遇？

Expansion into new geographic markets.
Development of new Biote-branded products.
Strategic partnerships with healthcare providers.
Increased focus on patient education and awareness.

BTMD面临哪些威胁？

Increased competition from alternative therapies.
Changes in regulations governing hormone therapies.
Economic downturn impacting patient spending.
Negative publicity regarding hormone optimization.

BTMD的竞争对手是谁？

Arcosa, Inc. — Offers infrastructure products and solutions. — (ABOS)
Acutus Medical, Inc. — Focuses on cardiac arrhythmia solutions. — (ACTU)
Anika Therapeutics, Inc. — Specializes in joint health solutions. — (ANIK)
Inovio Pharmaceuticals, Inc. — Develops DNA medicines. — (INO)
The Joint Corp. — Operates chiropractic clinics. — (JYNT)

Key Metrics

Price: $1.59 (+5.30%)
Market Cap: $71.0M
P/E Ratio: 1.80
MoonshotScore: 47/100

Analyst Price Target

Analyst Consensus Target: $3.75
Current Price: $1.59
Implied Upside: +135.8%

Company Profile

CEO: Bret Christensen
Headquarters: Irving, TX, US
Employees: 217
Founded: 2021

AI Insight

biote Corp. operates a medical practice-building business within the hormone optimization space. They offer a platform for practitioners to optimize patient hormone, vitamin, and mineral levels, and provide bioidentical hormone therapies and dietary supplements.

常见问题

What does biote Corp. do?

biote Corp. operates a medical practice-building business within the hormone optimization space. The company provides a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels. They offer bioidentical hormone therapies and recommend Biote-branded dietary supplements. Additionally, they sell sterile pellet insertion kits for men and women. Their business model is centered around empowering practitioners with the tools and resources needed to deliver effective hormone optimization treatments, while also generating revenue through product sales and platform usage.

Is BTMD stock a good buy?

BTMD stock presents a mixed investment profile. The company's high gross margin of 72.2% and a P/E ratio of 2.43 suggest potential undervaluation. Growth catalysts include the expansion of the Biote-branded product line and strategic partnerships. However, the may be worth researching risks associated with regulatory changes and competition. A balanced analysis of these factors is crucial before making an investment decision, considering both the growth potential and potential risks.

What are the main risks for BTMD?

The main risks for BTMD include potential changes in regulations governing hormone therapies, which could impact the company's ability to market and sell its products. Increased competition from alternative therapies and established healthcare providers also poses a threat. Additionally, the company's reliance on Biote-certified practitioners for revenue generation creates a dependency risk. An economic downturn could also impact patient spending on hormone optimization therapies, affecting the company's revenue. Negative publicity regarding hormone optimization could also damage the company's reputation and sales.